NLS Pharmaceutics Ltd - Warrants (25/09/2025) EBIT

The latest EBIT for NLSPW is $-7.7M as of June 2026. That compares with $-21M in the prior-year period — up 62.7% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, NLSPW's EBIT moved from $-21M to $-7.7M — a 62.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s operating scale or balance-sheet position.

Against Healthcare companies, NLSPW currently prints $-7.7M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s growth, margins, and balance sheet.

A EBIT figure of $-7.7M for NLSPW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting NLSPW's EBIT ($-7.7M), review year-over-year change from $-21M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.